These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24841321)

  • 1. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial.
    Mokhber N; Azarpazhooh A; Orouji E; Rao SM; Khorram B; Sahraian MA; Foroghipoor M; Gharavi MM; Kakhi S; Nikkhah K; Azarpazhooh MR
    J Neurol Sci; 2014 Jul; 342(1-2):16-20. PubMed ID: 24841321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis.
    Mokhber N; Azarpazhooh A; Orouji E; Khorram B; Modares Gharavi M; Kakhi S; Khallaghi H; Azarpazhooh MR
    Psychiatry Clin Neurosci; 2015 Oct; 69(10):649-57. PubMed ID: 25907350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment of Japanese multiple sclerosis patients: Follow-up study using BRB-N assessment tool.
    Yoshii F; Takagi S; Nagata E; Hasegawa Y; Kunika N; Maki F; Mochizuki H; Ogino M; Kuroiwa Y
    J Neurol Sci; 2015 Dec; 359(1-2):323-7. PubMed ID: 26671136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy).
    Moccia M; Loperto I; Lanzillo R; Capacchione A; Carotenuto A; Triassi M; Brescia Morra V; Palladino R
    BMC Health Serv Res; 2020 Aug; 20(1):797. PubMed ID: 32847587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon beta-1a (Avonex TM): clinical and MRI impacts].
    Vermersch P
    Rev Neurol (Paris); 1999; 155 Suppl 2():S13-9. PubMed ID: 10367320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ
    Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.
    Trojano M; Paolicelli D; Zimatore GB; De Robertis F; Fuiani A; Di Monte E; Livrea P
    Neurol Sci; 2005 Dec; 26 Suppl 4():S179-82. PubMed ID: 16388354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests].
    Selmaj K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z
    Neurol Neurochir Pol; 2003; 37(6):1163-83. PubMed ID: 15174231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the relative bioavailability of different interferon beta preparations.
    Deisenhammer F; Mayringer I; Harvey J; Dilitz E; Gasse T; Stadlbauer D; Reindl M; Berger T
    Neurology; 2000 Jun; 54(11):2055-60. PubMed ID: 10851362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, controlled, single-blind, 6-month pilot study to evaluate the efficacy of MS-Line!: a cognitive rehabilitation programme for patients with multiple sclerosis.
    Gich J; Freixanet J; García R; Vilanova JC; Genís D; Silva Y; Montalban X; Ramió-Torrentà L
    Mult Scler; 2015 Sep; 21(10):1332-43. PubMed ID: 25716880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
    Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu G; Martinelli V; Milani N; Milanese C; Moiola L; Patti F; Pilato V; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Mult Scler; 2005 Aug; 11(4):420-4. PubMed ID: 16042224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.